Patents by Inventor Meredith Wright

Meredith Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6375930
    Abstract: Compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle and methods for imaging, diagnosis and treatment using the loaded vesicle are provided. For example, liposomes or red blood cells loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. Liposomes or cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate can be photolysed, allowing for a photodynamic therapy effect at the site of lysis. Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a photodynamic therapeutic agent to a desired site with a high concentration of oxygen.
    Type: Grant
    Filed: November 20, 1997
    Date of Patent: April 23, 2002
    Assignees: Board of Regents, The University of Texas System, Pharmacyclics, Inc.
    Inventors: Stuart W. Young, Meredith Wright, Jonathan L. Sessler, Tarak D. Mody, Darren Magda
  • Publication number: 20020006378
    Abstract: Compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle and methods for imaging, diagnosis and treatment using the loaded vesicle are provided. For example, liposomes or red blood cells loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. Liposomes or cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate can be photolysed, allowing for a photodynamic therapy effect at the site of lysis. Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a photodynamic therapeutic agent to a desired site with a high concentration of oxygen.
    Type: Application
    Filed: November 20, 1997
    Publication date: January 17, 2002
    Inventors: STUART W. YOUNG, MEREDITH WRIGHT, JONATHAN L. SESSLER, TARAK D. MODY, DARREN MAGDA
  • Patent number: 6022959
    Abstract: Texaphyrin metal complex-oligonucleotide and -oligonucleotide analog conjugates are provided where the texaphyrin is bound to an internal linkage of the oligonucleotide or oligonucleotide analog, the conjugates having catalytic activity for the hydrolysis of ribonucleic acid. Further, conjugates demonstrating catalytic turnover are described, the conjugates being especially effective under conditions where the concentration of RNA target exceeds that of available conjugate.
    Type: Grant
    Filed: November 20, 1997
    Date of Patent: February 8, 2000
    Assignee: Pharmacyclics, Inc.
    Inventors: Darren Magda, Shaun P. Crofts, Meredith Wright
  • Patent number: 5763172
    Abstract: A method of phosphate ester hydrolysis including incubating a solution of an aqueous phosphate ester with a metallotexaphyrin complex under conditions and for a time sufficient to hydrolyze the phosphate ester. The metal is a metal cation having catalytic activity for ester bond hydrolysis in aqueous solution. Phosphate ester substrates include nucleic acid such as RNA, phosphoric anhydrides, phospholipids, and alkyl phosphate esters.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 9, 1998
    Assignees: Board of Regents, The University of Texas System, Pharmacyclics, Inc.
    Inventors: Darren Magda, Jonathan L. Sessler, Meredith Wright, Richard A. Miller, William C. Dow
  • Patent number: 5607924
    Abstract: Methods of cleavage of a polymer of deoxyribonucleic acid using photosensitive texaphyrins are disclosed. A preferred method of use is the site-specific cleavage of a polymer of deoxyribonucleic acid and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 4, 1997
    Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.
    Inventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Meredith Wright
  • Patent number: 5567687
    Abstract: A texaphyrin having substituents containing ethoxy groups, methods for using texaphyrins in photodynamic therapy, and cleavage of a polymer of deoxyribonucleic acid are disclosed. The in vivo treatment of tumors and atheroma is demonstrated using Lu(III)texaphyrin complexes. A preferred method of use is the site-specific cleavage of a polymer of deoxyribonucleic acid and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide.
    Type: Grant
    Filed: September 21, 1994
    Date of Patent: October 22, 1996
    Assignees: University of Texas, Pharmacyclics, Inc.
    Inventors: Darren Magda, Jonathan L. Sessler, Brent Iverson, Petra L. Jansen, Meredith Wright, Tarak D. Mody, Gregory W. Hemmi
  • Patent number: 5559207
    Abstract: A method of phosphate ester hydrolysis including incubating a solution of an aqueous phosphate ester with a texaphyrin metal complex. The metal is a metal cation having catalytic activity for ester bond hydrolysis in aqueous solution, in particular, a lanthanide metal cation, preferably Eu(III) or Dy(III). A preferred substrate is RNA and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directed molecule, preferably an oligonucleotide.
    Type: Grant
    Filed: April 14, 1994
    Date of Patent: September 24, 1996
    Assignees: Board of Regents, University of Texas, Pharmacyclics, Inc.
    Inventors: Jonathan L. Sessler, Daniel A. Smith, Richard A. Miller, Kevin L. Ross, Meredith Wright, William C. Dow, Vladimir A. Kr al, Brent Iverson, Darren Magda